Management of the neck in parotid carcinoma

American Journal of Surgery

Volumn 172, Issue 6, 1996, Pages 695-697

  Kelley, Daniel J ^a   Spiro, Ronald H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CHILD; CONFERENCE PAPER; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PAROTID GLAND CARCINOMA; PRIORITY JOURNAL; SEX DIFFERENCE;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NECK; PAROTID NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030457217     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00307-8     Document Type: Conference Paper

References (17)

1. Spiro RH, Huvos, AG, Strong EW. Cancer of the parotid gland. Am J Surg. 1975;130:452-459.
2. Spiro RH, Armstrong J, Harrison L, et al. Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg. 1989;115:316-321.
3. Lam KH, Wei WI, Lau WF. Tumours of the parotid - the value of clinical assessment. Aust N Z J Surg. 1986;56:325-329.
4. Califano L, Zupi A, Massari PS, Giardino C. Indication for neck dissection in carcinoma of the parotid gland. Our experience on 39 cases. Int Surg. 1993;78:347-349.
5. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992;69:615-619.
6. Poulsen MG, Tripcony LB, Kynaston B. Nodal recurrence in primary malignant epithelial tumours of the parotid gland. Australas Radiol. 1991;35:169-173.
7. Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F. Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. Eur Arch Otorhinolaryngol. 1995;252:139-142.
8. Ball AB, Fish S, Thomas JM. Malignant epithelial parotid tumours: a rational treatment policy. Br J Surg. 1995;82:621-623.
9. Byers RM, Piorkowski R, Luna MA. Malignant parotid tumors in patients under 20 years of age. Arch Otolaryngol. 1984;110:232-235.
10. Roberson DW, Chu FW, Yarington CT. Parotid cancer: treatment and results. Ear Nose Throat J. 1993;72:787-793.
11. Frankenthaler RA, Luna MA, Lee SS, et al. Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg. 1991;117:1251-1256.
12. Harrison LB, Armstrong JG, Spiro RH, et al. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol. 1990;45:52-55.
13. Gallo O, Franchi A, Bianchi S, et al. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer. 1995;75:2037-2044.
14. Armstrong JG, Harrison LB, Spiro RH, et al. Observations on the natural history and treatment of recurrent major salivary gland cancer. J Surg Oncol. 1990;44:138-141.
15. Tu GY, Hu Y, Jiang P, Qin D. The superiority of combined therapy (surgery and post-operative irradiation) in parotid cancer. Arch Otolaryngol. 1982;108:710-713.
16. Simpson JR. Radiation oncology: cancer of the salivary glands. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology. Philadelphia: JB Lippincott; 1987:513-528.
17. Spiro RH. Changing trends in the management of salivary tumors. Semin Surg Oncol. 1995;11:240-245.